Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer

Overview of attention for article published in Investigational New Drugs, June 2014

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 2 X posts from 1 X users, with an upper bound of 11,346 followers.

El inhibidor de CHK1 (LY2603618) es seguro en combinación con Cis + Pem en #CancerdePulmón. Dosis recomendada 275 mg. http://t.co/AJxLYfFEC4

CHK1 inhibitor in NSCLC (LY2603618): Ph1 combo with Cisplatin + Pemetrexed is safe (no DLTs). RP2D is 275 mg. #lcsm http://t.co/AJxLYfFEC4